Long-acting inhaled β2-agonists in the management of asthma: Recent advances and current recommendations

International Journal of Clinical Practice

Volumn 52, Issue 7, 1998, Pages 482-486

  Redington, A E ^a,b   Rees, P J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; SALMETEROL;

AIRWAY; ASTHMA; DRUG TOLERANCE; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; ETHANOLAMINES; FORCED EXPIRATORY VOLUME; GUIDELINES; HUMANS; PEAK EXPIRATORY FLOW RATE; TREATMENT OUTCOME;

EID: 0031731036     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Crane J, Pearce N, Flatt A et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989; i: 917-922.
2. Pearce N, Grainger J, Atkinson M et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-1981. Thorax 1990; 45: 170-175.
3. Grainger J, Woodman K, Pearce N et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax 1991; 46: 105-111.
4. Spitzer WO, Suissa S, Ernst P et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 501-506.
5. Sears MR, Taylor DR, Print CG et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-1396.
6. van Schayck CP, Dompeling E, van Herwaarden CLA et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ 1991; 303: 1426-1430.
7. Crane J, Burgess C, Beasley R. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline. Thorax 1989; 44: 136-140.
8. Weber RW, Smith JA, Nelson HS. Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration. J Allergy Clin Immunol 1982; 70: 417-422.
9. Kraan J, Koëter GH, Mark TW et al. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985; 76: 628-636.
10. 2-adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43: 674-678.
11. Arvidsson P, Larsson S, Löfdahl C-G et al. Formoterol, a new long-acting bronchodilator for inhalation. Eur Respir J 1989; 2: 325-330.
12. 2-adrenoceptor agonist: acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy 1989; 44: 264-271.
13. Gongora HC, Wisniewski AFZ, Tattersfield AE. A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects. Am Rev Respir Dis 1991; 144: 626-629.
14. 2-agonist formoterol. Am Rev Respir Dis 1991; 143: 998-1001.
15. Derom EY, Pauwels RA, Van Der Straeten MEF. The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours. J Allergy Clin Immunol 1992; 89: 811-815.
16. Newnham DM, Ingram CG, Earnshaw J et al. Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma. Respir Med 1993; 87: 439-444.
17. 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. Am Rev Respir Dis 1990; 142: 1147-1152.
18. Nowak D, Jörres R, Rabe KF et al. Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours. Eur J Clin Pharmacol 1992; 43: 591-595.
19. Bootsma GP, Dekhuijzen PNR, Festen J et al. Sustained protection against distilled water provocation by a single dose of salmeterol in patients with asthma. Eur Respir J 1997; 10: 2230-2236.
20. Derom EY, Pauwels RA. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. Thorax 1992; 47: 30-33.
21. Palmqvist M, Persson G, Lazer L et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484-2489.
22. Lindén A, Bergendal A, Ullman A et al. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximal relaxant effect and potency but not in functional antagonism. Thorax 1993; 48: 547-553.
23. 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 1991; 104: 665-671.
24. 2-adrenoceptor agonist. Br J Pharmacol 1987; 92: 590P (Abstract).
25. 2-adrenergic receptor. J Biol Chem 1996; 271: 24029-24035.
26. 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma. J Allergy Clin Immunol 1989; 84: 891-895.
27. 2-agonist. BMJ 1990; 301: 1365-1368.
28. Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients: an evaluation of asthma symptoms and the possible development of tachyphylaxis. Am Rev Respir Dis 1990; 142: 571-575.
29. Arvidsson P, Larsson S, Löfdahl CG et al. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991; 4: 1168-1173.
30. Dahl R, Earnshaw JS, Palmer JBD. Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir J 1991; 4: 1178-1184.
31. Kesten S, Chapman KR, Broder I et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis 1991; 144: 622-625.
32. Britton MG, Earnshaw JS, Palmer JBD. A 12-month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992; 5: 1062-1067.
33. Kesten S, Chapman KR, Broder I et al. Sustained improvement in asthma with long-term use of formoterol fumarate. Ann Allergy 1992; 69: 415-420.
34. Pearlman DS, Chervinsky P, LaForce C et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327: 1420-1425.
35. Lundback B, Rawlinson DW, Palmer JBD. Twelve month comparison of salmeterol as dry powder formulations in asthmatic patients. Thorax 1993; 48: 148-153.
36. D'Alonzo GE, Nathan RA, Henochowicz S et al. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994; 271: 1412-1416.
37. Jones KP. Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. Thorax 1994; 49: 971-975.
38. van der Molen T, Postma DS, Turner MO et al. Effects of the long-acting β-agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1996; 52: 535-539.
39. Juniper EF, Johnston PR, Borkhoff CM et al. Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol. Am J Respir Crit Care Med 1995; 151: 66-70.
40. Rutten-van Mölken MPMH, Custers F, Van Doorslaer EKA et al. Comparison of performance of four instruments :n evaluating the effects of salmeterol on asthma quality of life. Eur Respir J 1995; 8: 888-898.
41. British Thoracic Society, British Paediatric Association, Royal College of Physicians of London et al. Guidelines on the management of asthma. Thorax 1993; 48: S1-S24.
42. Greening AP, Ind PW, Northfield M et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-224.
43. Woolcock A, Lundback B, Ringdal N et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488.
44. Pauwels RA, Löfdahl C-G, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
45. Wilding P, Clark M, Coon JT et al. Effect of long term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 1997; 314: 1441-1446.
46. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327: 1198-1203.
47. Yates DH, Sussman HS, Shaw M et al. Regular formoterol treatment in mild asthma: effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med 1995; 152: 1170-1174.
48. Bhagat R, Kalra S, Swystun VA et al. Rapid onset of tolerance to the bronchoprotective effects of salmeterol. Chest 1995; 108: 1235-1239.
49. Kalra S, Swystun VA, Bhagat R et al. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996; 109: 953-956.
50. 2-agonist. Am J Respir Crit Care Med 1996; 154: 1603-1607.
51. Ramage L, Lipworth BJ, Ingram CG et al. Reduced bronchoconstriction against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88: 363-368.
52. Giannini D, Carletti A, Dente FL et al. Tolerance to the protective effect of salmeterol on allergen challenge. Chest 1996; 110: 1452-1457.
53. Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med 1994; 97: 29-37.
54. 2-adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995; 50: 497-504.
55. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346: 201-206.
56. Barnes N. Bronchodilation subsensitivity to salbutamol after salmeterol. Lancet 1995; 346: 968 (letter).
57. Ng HW. Bronchodilation subsensitivity to salbutamol after salmeterol. Lancet 1995; 346: 968 (letter).
58. Weinberger N. Bronchodilation subsensitivity to salbutamol after salmeterol. Lancet 1995; 346: 968 (letter).
59. Butchers PR, Vardey CJ, Johnson M. Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br J Pharmacol 1991; 104: 672-676.
60. Baker AJ, Palmer J, Johnson M et al. Inhibitory actions of salmeterol on human airway macrophages and blood monocytes. Eur J Pharmacol 1994; 264: 301-306.
61. Twentyman OP, Finnerty JP, Harris A et al. Protection against allergen-induced asthma by salmeterol. Lancet 1990; 336: 1338-1342.
62. Pedersen B, Dahl R, Larsen BB et al. The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X. Allergy 1993; 48: 377-382.
63. Gardiner PV, Ward C, Booth H et al. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994; 150: 1006-1011.
64. Kraft M, Wenzel SE, Bettinger CM et al. The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. Chest 1997; 111: 1249-1254.
65. Roberts JA, Bradding P, Walls AF et al. The influence of salmeterol xinafoate on mucosal inflammation in asthma. Am Rev Respir Dis 1992; 145: A418 (abstract).
66. Redington AE, Bradding P, Holgate ST. The role of cytokines in the pathogenesis of allergic asthma. Reg Immunol 1993; 5: 174-200.
67. Haahtela T, Järvinen M, Kava T et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331: 700-705.
68. Selroos O, Pietinalho A, Löfroos A-B et al. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995; 108: 1228-1234.
69. Overbeek SE, Kerstjens HAM, Bogaard JM et al. Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD). Chest 1996; 110: 35-41.
70. Redington AE, Howarth PH. Airway wall remodelling in asthma. Thorax 1997; 52: 310-312.
71. Boyd G, Morice AH, Pounsford JC et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-821.
72. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289.
73. O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996; 154: 876-880.